PTC Therapeutics is a biopharmaceutical firm developing and selling therapeutic treatments for rare genetic and neurological conditions affecting both children and adults globally. The company markets approved medications including treatments for Duchenne muscular dystrophy, spinal muscular atrophy, and various central nervous system disorders, while maintaining a pipeline of experimental therapies targeting conditions such as phenylketonuria and Huntington's disease. The New Jersey-based firm operates through partnerships with major pharmaceutical organizations and research institutions to advance its product development efforts.
1Y: 59.97 (-12.2%) · range 59.24–89.55
entry readiness 58 · MODERATE · exit proximity 0
Value area 60.08–78.68 · 99% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Oct 30, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -7.25% | +1.42% | mature |
| 40d | -13.88% | +1.42% | mature |